Gennova's mRNA vaccine gets DCGI nod to start phase-2 and 3 trials

Indigenous mRNA Covid-19 vaccine candidate, Gennova Biopharmaceuticals’ HGCO19, has got approval to start phase-2 and 3 clinical trials in the country.

If things go according to plan, the vaccine would be available in the market by the end of this year, sources said.

The Pune-based biotech firm submitted interim clinical data of the phase-1 study to the Central Drugs Standard Control Organisation (CDSCO).

The Vaccine Subject Expert Committee (SEC) reviewed the interim Phase-I data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study, a statement by the Ministry of Science & Technology said.

A